SVRA · Nasdaq · CIK 0001160308

Savara Inc

Savara Inc’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 25, 2026. Its EDGAR record lists 20 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$118.8M
Form 4 filings on record, past 12 months
20

Company overview

Legal name (as filed)
Savara Inc
Ticker
SVRA
SEC Central Index Key (CIK)
0001160308
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
AUSTIN, TX
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2482 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Savara Inc’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$43.0MFY2021-$38.1MFY2022-$54.7MFY2023-$95.9MFY2024-$118.8MFY2025
SVRA annual results
ItemFY2021
ended Dec 31, 2021
FY2022
ended Dec 31, 2022
FY2023
ended Dec 31, 2023
FY2024
ended Dec 31, 2024
FY2025
ended Dec 31, 2025
Revenue—————
Net income-$43.0M-$38.1M-$54.7M-$95.9M-$118.8M
Diluted EPS-$0.32-$0.25-$0.33-$0.48-$0.53
Total assets$176.6M$139.8M$177.6M$212.9M$253.4M
Cash and equivalents$34.0M$52.1M$26.6M$15.1M$33.2M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SVRA latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 13, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jun 8, 20268-KDirector or officer change; Charter, bylaws or fiscal year change; Shareholder vote results· period Jun 4, 2026Document · Index
Apr 24, 2026DEF 14ADefinitive proxy statement· period Jun 4, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Savara Inc, by form type:

4 ×20SCHEDULE 13G/A ×58-K ×4144 ×210-Q ×2S-8 ×1ARS ×1DEFA14A ×1DEF 14A ×1PRE 14A ×110-K ×1SCHEDULE 13G ×1
SVRA recent filings
FiledFormWhat it isOriginal
Sep 25, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 24, 2026Document · Index
Aug 11, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Jul 24, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 15, 2026Document · Index
Jun 22, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 22, 2026Document · Index
Jun 8, 20268-KDirector or officer change; Charter, bylaws or fiscal year change; Shareholder vote results· period Jun 4, 2026Document · Index
May 12, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 24, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 24, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 24, 2026DEF 14ADefinitive proxy statement· period Jun 4, 2026Document · Index
Apr 10, 2026PRE 14APRE 14A· period Jun 4, 2026Document · Index
Mar 20, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 18, 2026Document · Index
Mar 13, 20268-KMaterial agreement· period Mar 10, 2026Document · Index
Mar 13, 202610-KAnnual report· period Dec 31, 2025Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 17, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 16, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Feb 5, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 27, 20268-KMaterial agreement; New financial obligation· period Jan 26, 2026Document · Index
Jan 21, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jan 9, 20268-KRegulation FD disclosure· period Jan 9, 2026Document · Index
Dec 19, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 19, 2025Document · Index
Dec 18, 2025144Notice of proposed sale of securitiesDocument · Index
Dec 16, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025Document · Index
Dec 16, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025Document · Index
Dec 16, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025Document · Index
Dec 16, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025Document · Index
Dec 16, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 14, 2025Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Dec 11, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 9, 2025Document · Index
Dec 4, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 4, 2025Document · Index
Dec 4, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 2, 2025Document · Index
Nov 17, 20254Statement of changes in beneficial ownership (insider trade)· period Nov 14, 2025Document · Index

Insider filing activity

20 Form 4 filings appear in Savara Inc’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Texas

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001160308 and XBRL company facts. Savara Inc on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.